A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

VelosBio

Status and phase: Terminated; Phase 2

Conditions: ER-positive Breast Cancer; PR-negative Breast Cancer; Progesterone-receptor-positive Breast Cancer; ER-negative Breast Cancer; Non-squamous Non-small-cell Lung Cancer; HER2-negative Breast Cancer; Progesterone-receptor Negative Breast Cancer; Platinum-resistant Ovarian Cancer; Gastric Cancer; Triple-negative Breast Cancer; Estrogen-receptor-positive Breast Cancer; PR-positive Breast Cancer; Estrogen-receptor-negative Breast Cancer; Pancreatic Cancer; NSCLC

Treatments: Drug: Zilovertamab vedotin

Study type: Interventional

Funder types: Industry

Identifiers

NCT04504916

MK-2140-002 (Other Identifier)

VLS-101-0003 (Other Identifier)

2140-002

Details and patient eligibility

About

This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.

Full description

Participants enrolled prior to Amendment 3 will receive zilovertamab vedotin at 2.5 mg/kg given intravenously on Day 1 of repeated 21-day cycles. Participants enrolled after Amendment 3 will receive zilovertamab vedotin at 1.75 mg/kg given intravenously on Day 1 and Day 8 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer.
• Has metastatic disease that has progressed during or following previous treatment appropriate for the disease type
• Presence of radiographically measurable disease.
• Is willing to provide tumor tissue
• Has adequate organ function
• Has a negative test or adequate therapy for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C.
• Has completed all prior therapy.
• Female subjects of childbearing potential must have a negative serum pregnancy test.
• Both male and female subjects must be willing to use adequate contraception.

Exclusion criteria

• Has peripheral neuropathy of Grade >1.
• Has a malignancy involving the central nervous system.
• Has another major cancer.
• Has an uncontrolled ongoing infection.
• Has significant cardiovascular disease.
• Has a known diagnosis of liver cirrhosis.
• Is pregnant or breastfeeding.
• Has had major surgery within 4 weeks before the start of study therapy.
• Has known tumor resistance or intolerance to a prior MMAE-containing drug.
• Is concurrently participating in another therapeutic or imaging clinical trial.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

102 participants in 1 patient group

Zilovertamab Vedotin

Experimental group

Description:

Participants will receive intravenous (IV) zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W) or 1.75 mg/kg on Day 1 and Day 8 of each 21-day cycle (Q2/3W). Treatment will continue until progressive disease or discontinuation

Treatment:

Drug: Zilovertamab vedotin